|
Ranbaxy Intervenes in Mylan Generic Diovan Suit Against FDA
Ranbaxy has been granted the right to intervene as a defendant in a lawsuit that could determine whether Ranbaxy or its generic competitor Mylan will get 180-day exclusivity for generic versions of Novartis’ Diovan.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives